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Damage-associated molecular patterns (DAMPs) or cell death associated molecular patterns
(CDAMPs) are a subset of endogenous intracellular molecules that are normally hidden within living
cells but become either passively released by primary and secondary necrotic cells or actively exposed
and secreted by the dying cells. Once released, DAMPs are sensed by the innate immune system and act
as activators of antigen-presenting cells (APCs) to stimulate innate and adaptive immunity. Cancer cells
dying in response to a subset of conventional anticancer modalities exhibit a particular composition of
DAMPs at their cell surface, which has been recently shown to be vital for the stimulation of the host
immune system and the control of residual disease. Photodynamic therapy (PDT) for cancer has long
been shown to be capable of killing malignant cells and concomitantly stimulate the host immune
system, properties that are likely linked to its ability of inducing exposure/release of certain DAMPs.
PDT, by evoking oxidative stress at speciﬁc subcellular sites through the light activation of
organelle-associated photosensitizers, may be unique in incorporating tumour cells destruction and
antitumor immune response in one therapeutic paradigm. Here we review the current knowledge about
mechanisms and signalling cascades leading to the exposure of DAMPs at the cell surface or promoting
their release, the cell death mechanism associated to these processes and its immunological
consequences. We also discuss how certain PDT paradigms may yield therapies that optimally stimulate
the immune system and lead to the discovery of new DAMPs.
Introduction
The immune system and the cells that help in its efﬁcient working
are a host’s best defence against “foreign” pathogens/particles/
antigens which might prove to be detrimental (or even fatal) if not
controlled in time. Usually our immune system can carry out this
processwith panache due to its ability to proﬁciently detect various
molecular/biochemical patterns exhibited by a “foreign aggres-
sor”, e.g. ‘Pathogen-associated Molecular Patterns (PAMPs)’,
expressed by various pathogens.1,2 These molecular patterns can
be quite diverse in their biochemical nature, ranging from lipids
and proteins to lipoproteins/glycolipids and glycoproteins.1,3
However, it has recently come to attention that, by using similar
“molecular pattern detection senses”, the immune system can
detect the ‘danger signals’ associated with stressed or damaged
cells in the body and deal with them accordingly.1–3 This process
has been found in recent times to have implications in several
medical disorders including autoimmune diseases and cancer.1,2
aDepartment of Molecular Cell Biology, Faculty of Medicine, Catholic
University of Leuven, Campus Gasthuisberg ON1, Herestraat 49,
B-3000, Leuven, Belgium. E-mail: patrizia.agostinis@med.kuleuven.be;
Tel: +32.16.345715
bMolecular Signalling and Cell Death Unit, Department for Molecular
Biomedical Research, VIB, Belgium
cDepartment of Biomedical Molecular Biology, Ghent University, Belgium
† This article is published as part of a themed issue on immunological
aspects and drug delivery technologies in PDT.
One of the earliest ‘extensive’ discussions in the direction
of ‘danger signals’ was instigated by Polly Matzinger, when in
the course of outlining her opinions over the ‘self vs. non-
self discrimination by immune system’ she mentioned that cells
exposed to chemical/physical/biological stress have the ability to
emit ‘danger signals’, which are usually intracellularmolecules (cy-
toplasmic, nuclear or membrane-associated) that are not secreted
under normal conditions but, once released, could act as activators
of antigen-presenting cells (APCs) like dendritic cells (DCs).4 Over
the years however, the term ‘danger signal’ has been upgraded
to the umbrella term ‘Damage/Danger-associated Molecular
Patterns (DAMPs)’2,5 to outline the ‘immuno-modulatory resem-
blance’ of these molecules with the corresponding prokaryotic
counterparts – PAMPs. Moreover, there have also been some
additions to the deﬁnition of DAMPs/danger signals to ac-
commodate the developments done over the years. As it stands
currently, DAMPs are deﬁned as mostly intracellular molecules
(or molecules associated with cellular membranes in normal
conditions) that are normally hidden within/with healthy cells,
but tend to get exposed or secreted by damaged/dying cells
such that once outside they have a propensity to acquire im-
munostimulatory/immunomodulatory properties.1,2 DAMPs that
have been exposed or secreted have the ability, just like PAMPs,
to interact with pattern-recognition receptors (PRRs) – both
membrane-bound PRRs and intracellular PRRs.1,2 However, it
is worth mentioning here that this deﬁnition of DAMPs cannot
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be considered to be ‘exhaustive’ since it is currently incapable
of accommodating certain controversial or less studied signals
like “whole organelle-based danger signals”, e.g. complete mi-
tochondria (capable of activating the NLRP3 inﬂammasome),6,7
or danger signals originating from “non-intracellular pools”, e.g.
those resulting from the extracellular matrix (ECM), and not
to mention certain other types of danger signals/structures that
have not been characterized completely yet, e.g. tumour cell-
derived exosomes (see Table 1). Thus, in future, if the existence
of these DAMPs is proven to be incontrovertible then a new
deﬁnition might come into calling; till that happens, in the present
context (with respect to thewell characterized immunomodulatory
activities of other DAMPs) these danger signals might well be
regarded as “atypical DAMPs”. Alternatively, one could also
deﬁne DAMPs in accordance with the cellular processes during
which they are generated, e.g. Cell Death Associated Molecular
patterns (CDAMPs), Apoptotic Cell Associated Molecular Pat-
terns (ACAMPs) or cellular Stress AssociatedMolecular Patterns
(SAMPs). These nomenclature/deﬁnition dilemmas bring us to an
intriguing question, i.e. based on the type(s) of danger signals, can
the immune system differentiate between the sources where they
are coming from (i.e. injured tissue or stressed/dying/damaged
cells)? Or does it always react to these danger signals in the
same way (irrespective of the source)? The latter possibility is
hinted towards (but not conﬁrmed) by the fact that the receptors
perceiving DAMPs are shared with those for PAMPs,1,2 however
more research is required on the link between spectra of DAMPs
and the cellular sources. Further research into this subject might
be the only way to reach a proper nomenclature/classiﬁcation
scheme for DAMPs.
In recent times, several developments have been made in the
direction of associating a particular DAMP or their spectra
either with biochemistry of a speciﬁc cell death pathway or
with particular chemotherapeutic stressors (or biological stress).
These observations have not only inﬂuenced further exploration
in the direction of immunogenic cell death but they have also
led to a “race” in discovering/further characterizing new or
already known therapeutic agents/modalities that are capable of
sustaining aparticular spectrumofDAMPs.2 One such therapeutic
modality, which has known association with certain DAMPs but
needs a fresh re-look on these lines is – photodynamic therapy
(PDT).2,8–11 In the present review, we have discussed in detail
how PDT has the potential to not only help us discover new
DAMPs or better understand the exposure of known ones but also
solve certain glitches/conundrums (discussed later) associated
with them. Moreover, we have also reported certain observations
on the link between PDT and certain emerging DAMPs obtained
in our laboratory.
DAMPs and the crossroads between cell death and
immunogenicity
DAMPs tend to mediate the immunogenicity of dying/damaged
cells such that the type, diversity and mode of emergence (expo-
sure, secretion or release) of DAMPs are intricately associated
with the biochemistry of the particular cell death pathway in
question. Most prominent DAMPs associated with various cell
death pathways have been discussed in Table 1. In a ‘classical’
sense, the most immunogenic cell death pathway is considered
to be necrosis, since rapid loss of plasma membrane integrity
occurring during necrosis is always associated with the release of
various pro-inﬂammatory factors. On the other hand, apoptosis
in most cases is considered to be ‘tolerogenic’ and ‘autophagic’
cell death (i.e. cell death caused by autophagy) lacks a strongly
deﬁnable immunogenicity.2,12–14 This sketch of cell death pathway
immunogenicity has been modiﬁed by recent trends such as
the further characterization of the pro-inﬂammatory proﬁle of
necrosis and its diversity (Table 1), the emergence of ‘immunogenic
apoptosis’ as a new ‘subset’ of apoptosis and autophagic cell death
has shown the ability to release/expose DAMPs (discussed in
detail elsewhere).2,12–14
In therapeutic terms, the immunogenicity of apoptosis is
preferable for application rather than necrosis (or for that mat-
ter autophagic cell death) since necrosis can lead to harmful
immunological reactions15 (on the other hand, the extent of
immunological impact of autophagic cell death is as yet unchar-
acterized, thereby making it an uncertain modality to use in the
context of ‘immunochemotherapy’).2,8 Immunogenic apoptosis is
a phenomenon that has emerged recently and tends to be more-
or-less stressor dependent (as demonstrated for anthracyclines,
oxaliplatin, UVC light, g-irradiation and bortezomib).2,12,14,16 One
biochemical feature that has been found to be common amongst
all these agents is the ability to induce Endoplasmic Reticulum
(ER) directed stress either as a primary or secondary effect.2,12,14,16
Here, ER stress is a condition where the normal ER homeostasis
is disturbed by chemical/biological/chemotherapeutic stressors
(e.g. viral infections, oxidative injury, hypoglycaemia, hypoxia,
thapsigargin) thereby leading to imbalance between protein fold-
ing capacity and load.17 Moreover, in the case of agents like
anthracyclines, the involvement of ER stress probably associated
with the production of reactive oxygen species or ROS has been
implicated.14,16 Considering that ER stress has already been known
to associatewith immunological signalling, these newobservations
linking it with ‘critical’ DAMPs and immunogenic apoptosis are
intriguing. For more on this link between ER stress-based cell
death, inﬂammation andDAMPs, please refer to the recent reviews
by Verfaillie et al.,17 Hummasti & Hotamisligil,18 Hotamisligil19
and Kaser & Blumberg.20
Biochemically speaking, immunogenic apoptosis is supposed
to have all the main hallmarks of ‘physiological’ apoptosis
however the main difference is in the immunological proﬁle
which is immunostimulatory rather than tolerogenic. On these
lines, immunogenic apoptosis can be considered to possess
two main properties beyond ‘physiological’ apoptosis, i.e. (1)
exposure/secretion of (critical) ‘immunogenic signals’ or DAMPs
and (2) ability to activate the immune system (so as to cause
maturation of antigen-presenting cells which thenmight prime the
adaptive immune cells against the target cell antigens).2,8,12,14,16,21
However exposure/secretion of ‘critical’ DAMPs is one of the
most vital properties for immunogenic apoptosis as proved in
the case of apoptotic DAMPs like surface calreticulin (ecto-
CRT), surface HSP90 (ecto-HSP90) and extracellular ATP (exo-
ATP) (Table 1). The emergence of concepts associated with
DAMPs have opened up new vistas which might have ef-
fects on both sides of the line in terms of disease progres-
sion, a subject that has been dealt with brieﬂy in the next
section.
Photochem. Photobiol. Sci. This journal is © The Royal Society of Chemistry and Owner Societies 2011
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Table 1 Major Damage-associated Molecular Patterns (DAMPs) linked with necrosis, apoptosis and cell death accompanied by/caused by autophagy
and their association with PDT
Molecule/Component Immunomodulatory activity Association with PDT Ref.
Surface (outer leaﬂet of plasma membrane) exposed DAMPs
Phosphatidylserine
(PS)
PS normally resides in the inner leaﬂet of the plasma membrane, however
damaged/dying cells “scramble” it to the outer leaﬂet where it acts as an
important ‘eat me’ signal and interacts with multiple immune cells
receptors to help in efﬁcient phagocytosis and induction of
anti-inﬂammatory response. Also interacts with opsonins like: Annexin-V,
b2-glycoprotein (b2GP1), milk fat globule EGF/factor VIIC (MFG-E8)
and growth arrest-speciﬁc gene 6 (Gas6).
Apoptosis induced via
PDT has been associated
with PS exposure.
13,68
Heat Shock Proteins
(HSPs)
HSPs normally reside in various intracellular regions/organelles, however
under certain stresses, they have been known to be exposed on the
damaged/dying cell’s surface and mediate immunomodulatory processes.
More speciﬁcally, surface-exposed HSP70 and HSP90 have been found to
affect phagocytosis and antigen processing/presentation. HSP90 has been
found to deﬁne immunogenicity of dying cells.
HSPs like HSP70, HSP60,
GRP94 and GRP78 have
been associated with
Photofrin-PDT (Fig. 1).
2,13,35,36
Calreticulin (CRT) CRT normally resides in diverse intracellular regions/organelles, however
under certain particular stresses (mostly ER-directed) its presence on the
plasma membrane tends to enhance “strongly” (sometimes even before PS
exposure). Once on the plasma membrane, ecto-CRT has been shown to
act as an ‘eat me’ signal as well as assist in ‘increasing’ the
immunogenicity of the dying cells.
Hypericin-PDT can induce
ecto-CRT exposure (Garg
et al., unpublished data)
(Fig. 2).
2,13
Oxidized
Phosphatidylcholine
(Ox-PtC)
Ox-PtC has been reported to emerge speciﬁcally on the surface of the
apoptotic cells and postulated to play a role in their phagocytic clearance
(possibly via CD36).
Not known 45,46
Extracellularly released/secreted DAMPs
Heat Shock Proteins
(HSPs)
HSPs have been known (more often) to be released passively from dying
cells, however there is an instance reported of active release via a
non-classical secretory pathway as well. Secreted HSPs can act as carriers
of crucial tumour antigens, helping in their proper uptake and processing
by APCs. They can also trigger secretion of various pro-inﬂammatory
cytokines from immune cells. Recently it was shown that extracellular
HSP90b can inhibit activation of latent TGF-b1.
Passive release of HSP70
has been associated with
Photofrin-PDT (Fig. 1).
8,35,69
Peroxiredoxin 1 (Prx1) Prx1 can be passively released by dying cells, however there is evidence
towards active secretion via non-classical secretory pathway in non-small
cell lung cancer cells. It was recently shown that “secreted” Prx1 can
stimulate TLR4-dependent cytokine secretion (in DCs and macrophages).
Not known 70
Calreticulin (CRT) Extracellular CRT (exo-CRT) tends to act as an important chemotactic
agent as well as assists in wound healing.
Not known 13
HMGB1 HMGB1 normally resides within the nucleus however it has been reported
that necrotic and secondary necrotic cells might release HMGB1
passively, while cells dying with autophagy under the stress of
recombinant fusion protein diphtheria toxin-epidermal growth factor
(DT-EGF) have been reported to secrete HMGB1 actively. HMGB1 has a
very prominent cytokine-like property and tends to stimulate immune
cells into producing various pro-inﬂammatory cytokines.
Not known 2,13
BCL2 BCL2 mediates various intracellular functions, especially those relating to
regulation of cell death. It was recently reported that extracellular BCL2
might act as a cytoprotective DAMP, thereby reducing apoptosis and
tissue injury.
Not known 71
ATP, UTP ATP/UTP are normally conﬁned pre-dominantly in the intracellular
space, however it has been reported that they might be released passively
by necrotic cells and actively by apoptotic cells dying under particular
stresses. Extracellular ATP and UTP have the ability to assist in
chemoattraction of immune cells. In fact, ATP has been shown to activate
the NLRP3 inﬂammasome in macrophages/dendritic cells.
Hypericin-PDT can induce
exo-ATP secretion (Garg
et al., unpublished data).
8,13
Annexin A1 Normally conﬁned to internal space, annexin A1 has been observed to be
externalized on secondary necrotic cells (but not primary apoptotic) and
cause prevention of cytokine production in macrophages. Annexin A1 is
known to be potently anti-inﬂammatory in nature.
Not known 72
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci.
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Table 1 (Contd.)
Molecule/Component Immunomodulatory activity Association with PDT Ref.
Other major
extracellular DAMPs
associated with
apoptosis
Endothelial Monocyte-activating Polypeptide II (EMAPII), Cross-linked
dimer of ribosomal protein S19 (dRP S19), lysophosphatidylcholine
(LPC) and fragments of human tyrosyl tRNA synthetase (TyrRS) are
some of the ‘ﬁnd me’ signals released from apoptotic cells (either actively
or passively depending on the conditions). Acting as a chemotactic factor
for attracting various immune cells is a major extracellular function of
most of them. LPC can also assist in DC maturation.
Not known 2,13
Other major
extracellular DAMPs
associated with
necrosis
S100/Calgranulin protein family members (S100A8, S100A9, S100A12),
Hepatoma-derived Growth Factor (HDGF), monosodium urate (MSU),
SAP130, galectins, thioredoxin and cathelicidins are ‘ﬁnd me’ signals
passively released by necrotic cells. These molecules mediate a number of
processes ranging from attracting various immune cells (chemotactic
factor) and interacting with vital immune cell receptors (like
TLR4/RAGE) to inducing secretion of pro-inﬂammatory
cytokines/enzymes from immune cells.
Not known 2,13
End-stage products based DAMPs
Genomic DNA,
mRNA, snRNPs
They are usually released by dead cells (necrotic or secondary necrotic)
and tend to activate various pro-inﬂammatory processes.
Not known 13
Mitochondrial
DAMPs (mtDAMPs)
DAMPs derived from mitochondria (like mitochondrial DNA and
N-formyl peptides) have been shown to be capable of activating strong
inﬂammatory response, however their relevance in a cell death modality
set-up is yet to be fully tested. Recently it was reported that even whole
mitochondria released from necrotic cells are capable of activating the
inﬂammasome.
Not known 7,73,74
“Atypical DAMPs” originating from Extracellular Matrix (ECM) components
Biglycan Interacts with TLR2/4 and P2X4/P2X7 receptors on macrophages and
induces NLRP3/ASC inﬂammasome-dependent IL-1b production. It can
also interact with various cytokines.
Not known 75,76
Hyaluronan Similar to biglycan, hyaluronan has been reported to interact with
TLR2/4 receptors as well as activate NLRP3 inﬂammasome-dependent
IL-1b production.
Not known 76
Versican Versican was recently reported to interact with the TLR2/6/CD14
complex thereby activating tumour-inﬁltrating myeloid cells and assisting
in tumour metastasis.
Not known 76
Fibrinogen A known ligand for TLR4 that has been shown to activate macrophage’s
chemokine synthesis program.
Not known 76
Heparan Sulfate
fragments
Acts as a TLR4 ligand on DCs and assists in their maturation as well as
later T-cell stimulation.
Not known 76
Fibronectin extra
domain A
Known to activate expression of genes associated with TLR4-dependent
inﬂammatory response.
Not known 76
Tenascin-C Promotes TLR4-dependent synthesis of inﬂammatory cytokines. Not known 77
“Uncharacterized” DAMPs
Tumour cell-derived
exosomes
Exosomes are small lipid-bilayer vesicles reported to be released from
tumour cells recently. Exosomes are considered to be strongly
immuno-modulatory since they are enriched in heat shock proteins (like
HSP70 and HSP90), tetraspanins and MHC complexes. It has been
reported that DCs can use exosomes for proper cross-presentation and
subsequent T cell activation. In fact, it has been a common knowledge for
some time that DCs secrete exosomes and use them as “communication
vehicles” amongst themselves. However the exact “DAMP-ness” of
exosomes (with respect to dying/stressed cells) is yet to be characterized
fully.
Not known 78,79
Note: Here “passive” refers to release in presence of plasma membrane permeabilization while “active” means secretion/surface exposure in presence of
negligible/non-signiﬁcant plasma membrane permeabilization.
Photochem. Photobiol. Sci. This journal is © The Royal Society of Chemistry and Owner Societies 2011
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DAMPs: from bench-side research to bed-side reality
DAMPs are exposed, secreted actively or released passively in
a manner that depends on the type of damage or type of
stressors, as discussed previously. Once in the extracellular space,
DAMPs mediate various immunological processes. However
the point to ponder is whether the immunological processes
activated by DAMPs help ‘against’ a disease’s progression or
favour its progression (since DAMPs can be immunogenic/pro-
inﬂammatory as well as anti-inﬂammatory)? Processes associated
with certain DAMPs (e.g. in the case of exo-ATP and ecto-
CRT) have been recently shown to be capable of uniting tumour
cell kill and revival of anti-tumour immunity within a ‘single
paradigm’ thereby opening up a new area in our ‘therapeu-
tic war’ against cancer.2 On the other hand however, certain
DAMPs (e.g. HMGB1) have been suspected to promote the
tumour-driven inﬂammatory environment as well as the processes
driving inﬂammatory or autoimmune diseases15 (discussed later
brieﬂy). Either way, the knowledge we gain about DAMPs
and their mechanism/kinetics could help us in bettering our
treatment strategies against certain diseased conditions in clinical
settings.
Up front, knowledge about DAMPs could help us in making
proper decisions about which chemotherapeutic drugs should be
more or less preferred for a particular condition.Also, presence (or
absence) of particular DAMPs could serve the purpose of being
‘biomarkers’ thereby assisting in diagnostics or prognostics either
towards identiﬁcation of the disease’s stage or towards the identi-
ﬁcation of the extent of inﬂammation associated with that disease.
For example, it was recently shown in stage IIIB colon cancer pa-
tients that higher expression levels of the DAMP calreticulin were
associated with increased tumour-inﬁltration by T-lymphocytes,
both of which in turn where postulated to be associated with
higher 5 year survival rate of patients.22 Apart from this, knowledge
about DAMPs can also help us in improving certain vaccination
strategies employed against cancer. For instance, ‘autologous’
(killed) tumour cell based-vaccines23,24 and ‘autologous’ dendritic
cell (DC)-based vaccines25,26 have shown considerable promise
mitigated by instances of failures within clinical settings.27,28 Cur-
rently, such vaccine preparationsmostly involve simple lysis or heat
shock-based killing of tumour cells, treatments which might not
be ‘strongly’ immunogenic. However, our knowledge of treatment
strategies that induce immunogenic apoptosis associated with
crucial DAMPs could help us in applying them in preparation
of the above-mentioned vaccines so as to improve their adaptive
immune systempriming abilities.Also, onemay goone step further
and add a puriﬁed version of particular DAMPs to the vaccine
preparations in order to improve the ‘immunogenicity’ of the
vaccine.
As evident from the above discussion, in terms of DAMPs,
there are several things that are of utmost importance for further
investigation to completely exploit their clinical potential, such
as: further search for agents/modalities capable of inducing
immunogenic cell death, characterization of new (hopefully more
crucial) DAMPs and identiﬁcation of molecular pathways behind
active surface exposure/secretion of DAMPs. In the following
sections, the DAMPs associated with PDT and the possibilities
offered by PDT in bettering the DAMP-based paradigms have
been discussed in detail.
DAMPs and PDT: a revival in the calling!
The link between PDT and DAMPs is in no way new, as there are
already ‘solid’ as well as promising observations available about
not only association of particular DAMPs with PDT but also
the immunogenicity of PDT-treated cancer cells, as well as the
ability of PDT-treated cancer cells to help in ‘revival’ of anti-
tumour immunity both in pre-clinical as well as clinical settings.8
For more on PDT and the immunological processes activated by
it, please refer to reviews byGollnick&Brackett,29 Garg et al.8 and
Castano et al.30 It is well-known that PDT-killed tumour cells tend
to induce stronger anti-tumour immunity in vivo than tumour cell
lysates produced via treatments like ionizing irradiation, freeze-
thaw or UV irradiation.8 Based on these premises PDT-based
whole tumour cell killed vaccines have been produced and have
shown good promise in pre-clinical models (and led to phase I
clinical trial on similar lines),11,29 thereby further substantiating
the stand that PDT-treated cancer cells are highly immunogenic.
Such observations were the primary reasons in the past which lead
researchers to probe the link between PDT and DAMPs.
It is well known that PDT is capable of inducing all three
types of cell death modalities, i.e. necrosis, ‘autophagic’ cell death
and apoptosis,31 however what would be interesting to conﬁrm
is whether the concept of ‘PDT-induced cell death associated
DAMPs’ exists.8 For necrosis, (inducing) agent-to-agent variations
have not been reported to change the spectra of necrotic DAMPs.
Thus, although PDT-induced necrosis would not be expected
to have signiﬁcantly different spectra of DAMPs, it might well
be associated with DAMPs that are more chemically modiﬁed
under oxidative stress. However, this latter possibility has not
been investigated yet. It is known now that the immune cells in
terms of phagocytosis deal with necrosis in a different manner
than apoptosis,32 however whether this also applies to antigen
processing is a matter of debate. Thus in clinical settings, due
to very limited amount of data, it is tough to speculate or
propose if PDT-induced necrosis would be harmful or beneﬁcial.
If the DAMP spectra associated with PDT-induced necrosis is
found to be “biochemically different” from normal necrosis then
there is a possibility of it being beneﬁcial but this needs further
investigation. Similarly, nothing substantial is known about the
spectra of DAMPs associated with PDT-induced autophagic cell
death. On the other hand, PDT-treated apoptotic cells have
been predominantly associated with heat shock protein (HSP)-
based DAMPs. HSPs are considered to be a well-known group
of DAMPs33 due to their high hydrophobicity, a biochemical
character considered to be critical for DAMP-like behaviour.3
HSPs are considered to be ‘strongly’ immunostimulatory in all
extracellular forms, i.e. surface-exposed, secreted (actively or
passively) and in the form of passively-released complexes with
lipid membranes/tumour-derived peptides (Table 1). For more on
DAMP-like activity and immunomodulatory potential of HSPs,
please see reviews by Pockley,34 Tsan & Gao33 and Garg et al.2,8
In the context of PDT, it has been shown that Photofrin-PDT-
treated SCCVII cancer cells can surface exposemolecules like ecto-
HSP70, ecto-HSP60 and ecto-GRP94 (GRP – glucose-regulated
protein) (Fig. 1) more robustly in apoptotic state rather than
in healthy conditions.35 Moreover, these PDT-treated cells were
also found to secrete exo-HSP70, a DAMP that according to
present knowledge is suspected to be released passively, i.e. after
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci.
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Fig. 1 DAMPs associated with PDT. It has been shown that Photofrin-PDT leads to different DAMP spectra on the surface of same cancer cells
depending on the treatment setting, i.e. in vitro or in vivo. In in vitro setting, Photofrin-PDT causes surface exposure of HSP60, HSP70 and GRP94 on
the treated cancer cells accompanied/followed by extracellular release of HSP70. However, in in vivo settings, Photofrin-PDT causes HSP70 and GRP78
surface exposure on the treated cancer cells. On the other hand, neutrophils and macrophages derived from the same Photofrin-PDT treated tumour site
tend to expose HSP60, GRP94 and GRP78 on their surface.
signiﬁcant membrane permeabilization.35 Intriguingly, when the
authors extended these in vitro experiments to in vivo settings,
they found that the spectrum of DAMPs exposed on the PDT-
treated SCCVII tumour cells was different such that while they
still engaged ecto-HSP70 they no longer exposed ecto-HSP60 and
ecto-GRP94, but exposed yet another molecule, i.e. GRP78, on
their surface (Fig. 1).35 To our knowledge, this is the only study
where surface-exposed DAMPs have been reported to differ in
the same cancer cells between in vitro and in vivo treated settings.
Whether these effects are speciﬁc for PDT or can be extended
to other modalities is an open question. Apart from that, these
authors also reported that neutrophils and macrophages derived
from the PDT-treated tumour microenvironment surface-exposed
molecules like HSP60, GRP78 and GRP94 (Fig. 1),35 thereby
further implying the possibility of variations in emergence of
DAMPs based on cell-type differences. These authors implicated
ecto-HSP70 in supporting the opsonisation of cancer cells by the
C3 complement protein.11 It was later reported that Photofrin-
PDT-based ecto-HSP70 exposure tends to relate closely with the
changes in mitochondrial transmembrane potential.36 Depending
upon the type of cell death induced by PDT, the associated
DAMPspectra can lead to various effects ranging from strong pro-
inﬂammatory reaction (which might be harmful in certain cases)
to robust pro-inﬂammatory reaction which can help in priming of
the immune system against the tumour antigens.12,31,37 Clinically,
the latter is preferred; however, since the knowledge about PDT-
associated DAMP spectra is limited, it is tough to envisage the
clinical PDT settings that might be applied to produce a certain
beneﬁcial effect. This deserves further attention in near future.
The PDT-DAMP link discussed above has not been re-analyzed
in the light of latest evidence that has emerged in the ﬁeld
of DAMPs, both in terms of the emerging DAMPs as well as
the molecular pathways involved in active exposure/secretion of
emerging and well-known DAMPs. In the following sections, we
discuss how PDT might lead the way ahead in terms of DAMPs
and immunogenic cell death.
DAMPs and photo-oxidative stress: how can PDT lead
the way ahead?
It would be ﬁtting to postulate that what we know currently
about DAMPs, as a whole, is only a tip of the iceberg. Thus,
needless to say, several conundrums and glitches associated with
DAMPs have either not received enough attention or have not
been fully answered (e.g. how does oxidative modiﬁcations affect
DAMPs?What are the ‘pools-of-origin’ of variousDAMPs?What
molecular components are involved in active exposure/secretion
of DAMPs? What is the role of autophagy in DAMPs expo-
sure/secretion?).We envisage that the unique nature of PDTmight
help us solve some of them if not all (or at least provide valuable
inputs). In the following sub-sections we have dealt with certain
scenarios in which PDT can ‘come to the rescue’ (or has already
been shown to be of major importance).
Organelle-directed stress and DAMP translocation/secretion
mechanisms: how can PDT enlighten us?
Considering the available knowledge underlying the release
mechanisms, there exist more (characterized) DAMPs which
are passively released by dying/damaged cells than actively
exposed/secreted (see Table 1). However this difference might not
be because of DAMP molecules’ preference towards a particular
extracellular domain but rather due to our limited knowledge
of DAMPs as well as differences in biochemistry of a particular
Photochem. Photobiol. Sci. This journal is © The Royal Society of Chemistry and Owner Societies 2011
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Fig. 2 Photo-oxidative ER stress via hypericin-PDT causes surface exposure of calreticulin (ecto-CRT). T24 human bladder carcinoma cells were treated
with Mitoxantrone/MTX (1 mM MTX for 4 h) and Hypericin-PDT (150 nM hypericin for 16 h and 2.16 J cm-2 irradiation with visible light followed by
recovery at 1 h post-PDT). MTX is the positive control for ecto-CRT exposure. After treatment, the cells were ﬁxed and immunostained for ecto-CRT
(primary antibody: rabbit anti-calreticulin polyclonal antibody, cell signaling; secondary antibody: Alexa Fluor-488 goat anti-rabbit IgG, Invitrogen)
followed by DAPI-based staining for the nucleus. Scale bar = 15 mm.
cell death pathway. Nevertheless, while molecular pathways for
some actively translocated/secreted DAMPs have been described
yet for other they are either incomplete or less characterized.
Ecto-CRT remains one of the DAMPs for which a molecular
pathway has been described in some detail,14 but there are still
areas within that pathway that need further attention. One thing
that emerged from the studies on ecto-CRT is that the ‘pool-of-
origin’ of DAMPs from within a sub-cellular location of a cell
might ﬁnally inﬂuence the type of pathway that the corresponding
DAMP eventually follows. For example, ER stress in the case of
ecto-CRT sets the tone for molecular components of the secretory
pathway and the Unfolded Protein Response (UPR) signalling to
play a role in translocating CRT to the surface.14,16,21 However,
in this case, the agents used for exerting ER stress-mediated
ecto-CRT translocation (especially anthracyclines) are known to
produce ROS as a secondary effect of cellular damage such that
their ‘action’ is not exclusively directed towards ER but also other
organelles.38 Thus, to further characterize this pathway we need
a stressor that has ROS-based ER stress as its primary effect.
Similarly, in the case of other DAMPs like exo-ATP, ecto-/exo-
HSP70, ecto-HSP90, not only the ‘pool-of-origin’ is elusive but
also the exact molecular components involved are unknown.
The uniqueness of PDT as a therapy could be of vital
importance here, both for further characterization of molecular
pathways behind DAMP translocation/secretion and for the
identiﬁcation of their ‘pool-of-origin’. PDT and its effects heavily
depend upon the sub-cellular localization of the photosensitiser
(PS) and luckily there is a signiﬁcant panel of photosensitisers
available with various different sub-cellular localization proﬁles.31
Moreover, ROS-based stress directed towards the organelle where
the photosensitiser localizes is a primary effect of PDT, e.g.
hypericin (localizes predominantly in the ER)-based PDT would
produce photo-oxidative ER (p-ox ER stress) stress while 5-
ALA (localizes in the mitochondria)-based PDT would produce
photo-oxidative mitochondrial stress.30,31 It is worth mentioning
here that correlation between a particular spectrum of DAMPs
and stress on a particular sub-cellular site or organelle is a
relatively new and highly unexplored concept. For instance, based
on the observations showing that ER-directed and ROS-based
stress causes surface exposure of ecto-CRT, it is presumable
that ecto-HSP70 exposed after Photofrin-PDT requires pathways
originating from the subcellular sites where Photofrin-PDT exerts
its primary photodamage,39,40 namely the ER, mitochondria or
Golgi complex. However, further investigations are required to
establish such correlations, since these can inﬂuence further studies
on molecular pathways.
To this end, we have been investigating the DAMP spectra
associated with photo-oxidative ER stress (p-ox ER stress) exerted
by especially hypericin-basedPDT (Hyp-PDT) in our laboratory.41
We have observed that p-ox ER stress induces ‘pre-apoptotic’
enhancement in surface exposure of calreticulin (ecto-CRT) (see
Fig. 2) as quickly as 30min after PDT in a dose-dependentmanner,
in T24 human bladder carcinoma cells (Garg et al., unpublished
results). Interestingly, Photofrin-PDT, although shown to be ca-
pable of exerting ROS-based ER stress,40 does not incite enhanced
surface exposure of ecto-CRT in the same cells (J. Golab, personal
communication). This difference between photofrin-PDT and
hypericin-PDT is rather intriguing and might be explained by the
magnitude of p-ox ER stress generated since photofrin localizes
in the ER to a lesser extent than hypericin, or by distinct PDT-
mediated effects on processes required to translocate CRT from
the ER to the plasmamembrane.We also observed that Hyp-PDT
induces ‘pre-apoptotic’ active exo-ATP secretion and late stage
passive release of DAMPs like HSP70, HSP90 and CRT (Garg
et al., unpublished results). Overall these observations reveal the
potential of Hyp-PDT in causing exposure/secretion of ‘critical’
DAMPs and also adds this modality in a rather ‘small club’ of
anti-cancerous therapeutic agents/modalities capable of exposing
immunogenic signals like ecto-CRT.14,16
Oxidative modiﬁcations of DAMPs: to be or not to be?
The possibility of immunomodulatory/immunostimulatory po-
tential of a DAMP being neutralized via oxidative modiﬁcations
is a debate that has risen recently. Apparently, under natural
conditions, the sub-cellular location from where a DAMP is
derived can ﬁnally decide the kind of modiﬁcation it might
undergo once outside the cell.37,42 The redox variations within
the cells and outside mostly are deﬁned by the thiol redox status
such that the cytosol is highly reducing (due to thiol-regulating
enzymes like thioredoxin-thioredoxin reductase; reduced and
oxidized glutathione molecules maintained in a reducing 100 : 1
ratio), lumens of all secretory pathway components including ER
is highly oxidizing (reduced and oxidized glutathione molecules
maintained in an oxidizing 3 : 1 ratio), nucleus is highly reduc-
ing while the extracellular space is strongly oxidizing (due to
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci.
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the number of reducing enzymes and abundance of oxidizing
agents).37,42 Understandably, the proteins from these sub-cellular
regions are accustomed to the redox status of that region such
that proteins in the cytosol and nucleus are highly susceptible
to oxidation-based neutralization due to presence of cysteine
residues with free sulfhydryl groups. On the other hand, proteins
derived from secretory pathway components like the ER are not
because their cysteine residues are linked by disulﬁde bonds,
thereby providing extra stability in oxidizing environments.42
Thus DAMPs derived from nucleus and cytosol might be more
susceptible to extracellular space-based oxidation than those
derived from the Golgi or the ER, a claim substantiated by certain
recent observations. For instance, a predominantly cytosolic
protein, S100A8 (Table 1), which tends to act as a DAMP
when secreted and stimulates recruitment of myeloid cells to
the site of inﬂammation, can be oxidatively neutralized such
that the oxidized form is chemotactically inactive.43 Similarly,
HMGB1, a well-known DAMP originating from the nucleus
(Table 1), has been shown to be susceptible to oxidation-based
neutralization44 although not in the context of extracellular space-
based oxidation but rather oxidation via ROS produced from
mitochondria because of caspase activity. The latter work also
reasoned that the type of cell death pathway may also govern the
oxidative state of certain DAMPs, e.g. caspase activation during
apoptosis causes mitochondria-instigated HMGB1 oxidation44
but probably not under necrosis, although the mechanism of
this differential outcome between apoptosis and necrosis remains
enigmatic. However, in the case of cells dying through necrosis,
the extracellular oxidative environment comes into the picture,
thereby making this a moot case.
Therefore the debate centers around some still unresolved
questions like: does oxidation-based neutralization theory apply
to all DAMPs? This discussion becomes intriguing if we drag
a ROS-based modality like PDT into the picture since ROS
produced by PDT might be expected to affect DAMPs. While
this might be considered puzzling, evidence derived from PDT
treatments both in vitro and in vivo points towards anything
but inactivation of immunostimulation.8 PDT-treated cancer cells
have been reported to be ‘strongly’ immunogenic and PDT-
derivedHSPs are usually observed to remain immunostimulatory.8
In fact, it has been proposed that photo-oxidation via PDT
might actually be immunologically beneﬁcial such that PDT-based
protein unfolding events and membrane changes might reveal
certain neo or cryptic antigens.8 Thus, although there are no such
indications from immunological data generated after PDT, we still
need to investigate whether ROS-based modiﬁcations of certain
DAMPs by PDT could inactivate them.
It is worth mentioning here that in the context of DAMPs,
oxidationmight not always be considered to be counter-productive
since its effects tend to be biomolecule-dependent andDAMPs (as
mentioned previously) are not always protein based in nature.
Lipid or lipid-based molecules (e.g. phospholipids) have also
been documented to have DAMP-like activity (Table 1). In fact,
oxidized phospholipids (Ox-PL) have been documented to be
attractive to both humoral and cellular innate immune responses
such that their presence on apoptotic cells has been postulated
to assist in binding with macrophage scavenger receptors like
SR-B1 and CD3645,46 and in DC maturation regulation.47 Ox-
PL have been reported to act as ligands for PRRs and have been
found to be capable of activating a TLR4-based signaling pathway
independent of NFkB.48 In fact, it has been proposed that in the
case of phospholipids, oxidation leads to creation of ‘new’ epitopes
recognizable by antibodies.48 Observations on Ox-PL and their
behavior have led the researchers to postulate the ‘Lipid Whisker
Model’, an extended variant of the Fluid Mosaic Model.49 As
per the Fluid Mosaic Model, the amphipathic phospholipids are
supposed to have their hydrophobic fatty acyl chains hiddenwithin
the membrane interior while the hydrophilic polar headgroups are
supposed to be oriented towards the aqueous environment.49 How-
ever, as per the ‘Lipid Whisker Model’, when cellular membranes
undergo lipid peroxidation (e.g. during apoptosis or inﬂammation)
the resulting oxidation causes previously hydrophobic portions
of fatty acids to move towards the aqueous exterior thereby
facilitating their recognition by PRRs.49 More speciﬁcally, it has
been observed that the oxidized form of phosphatidylcholine
speciﬁcally tends to emerge on the apoptotic cells and possibly
helps in their clearance by phagocytes.45 Researchers have also
shown that phosphatidylserine (PS) the ‘classical’ lipid-based ‘eat
me’ signal (Table 1) tends to bind better to CD36 phagocytosis-
assisting receptor on macrophages when in oxidized form.50 All
this taken together means these Ox-PLs present an interesting
prospect that deserves further investigation. Interestingly, PDT
has been known for some time to cause considerable lipid
peroxidation, a process that has been found to play an important
role in PDT-mediated cell death and inﬂammatory processes.51,52
Thus, it would be worth investigating if PDT-mediated lipid
peroxidation enhances immunogenicity of PDT-treated cells and
their phagocytosis.
Cell death accompanied by autophagy and DAMPs: how beneﬁcial
can this link be?
Autophagy accompanying cell death has recently shown the poten-
tial to cause ‘active’ secretion of HMGB1,53 a well-known DAMP
and the ability to affect the proteome of the cell membrane.2,54
Interestingly, it was recently shown that cytosolic HMGB1
is capable of regulating starvation-induced autophagy, thereby
further shedding light on a possible link between autophagic
processes and HMGB1.55 However, it has not been characterized
yet if in long run autophagy accompanying cell death helps, in
terms of immunological impact. PDT is one of those therapeutic
modalities which can convincingly induce cell death accompanied
by or caused by autophagy in cancer cells, a subject that has been
a topic of many investigations in recent times.31,56–58 We envisage
that the study of DAMP spectra and immunogenicity in cancer
cells that, due to genetic defects in apoptotic pathway, undergo
autophagic cell death after PDT could help us in further answering
the conundrum of whether autophagy can help by enhancing
immunogenicity or reduce it.
DAMPs and their ‘alter egos’: where does PDT ﬁt in the story?
The discussions above mostly concentrate on the ‘good’ facet of
DAMPs, i.e. the scenario where DAMPs could help us against
diseases like cancer by pro-actively activating the immune system
against cancerous lesions. However in recent times it has been
revealed that certain DAMPs (especially HMGB1) have an ‘alter
ego’ which might be responsible for them driving certain
Photochem. Photobiol. Sci. This journal is © The Royal Society of Chemistry and Owner Societies 2011
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non-infectious inﬂammatory/autoimmune diseases, e.g.
rheumatoid arthritis, systemic lupus erythematosus (SLE),59
scleroderma59 and renal autoimmune tissue injury.60 A link has
been postulated between the DAMP-associated pro-inﬂammatory
programand the progression of these diseases.However, it is rather
hard to ﬁt PDT within this story since PDT that is associated
with DAMPs exposure and secretion has actually been in use for
treatment of various non-infectious inﬂammatory/autoimmune
diseases with positive results, e.g. psoriasis,61 psoriatic arthritis,62
rheumatoid arthritis,63,64 scleroderma,8,65 vulvar lichen sclerosus66
and autoimmune skin ulcers.67 PDT-based treatment of these
diseases has been considered to be promising, meaning that the
relationship between DAMPs and inﬂammatory/autoimmune
diseases needs a ‘fresh re-look’ on the lines of PDT. It is possible
that in these settings PDT might be proving to be beneﬁcial due
to ‘production’ of anti-inﬂammatory DAMPs or by inactivating
certain ‘problematic’ inﬂammatory DAMPs (possibly via ROS),
however both these possibilities need further investigation.
Nevertheless, one point is clear with this backdrop: that PDT
has considerable beneﬁcial immunomodulatory potential in
terms of disease management even if the diseases are originally
inﬂammation-associated/-driven.
Concluding remarks
DAMP-related research has been around for a considerable time
and, while the complete extent and diversity up to which cells can
expose DAMPs is still to be characterized, several ‘new’ DAMPs
have emerged recently.Moreover, major effort needs to be invested
on getting a better knowledge about the link between a particular
DAMPandaparticular cell death pathway aswell as themolecular
pathways underlying the extracellular emergence of DAMPs.
Considering the uniqueness of PDT in terms of its settings, and
its proven immunogenic character, we can safely assume that PDT
holds great promise not only in terms of ‘exposing’ as yet unknown
DAMPs but also in terms of shedding more light on the molecular
pathway underlying the translocation/secretion of these DAMPs.
Moreover, urgent attention is needed to characterize the presence
of immunogenic apoptosis following PDT so that this treatment
modality can be optimized for clinical induction of immunogenic
cell death in tumours.
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ATP Adenosine Triphosphate
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